<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0820">
 <label>164</label>
 <element-citation publication-type="journal" id="rf0815">
  <person-group person-group-type="author">
   <name>
    <surname>Gómez-Enjuto</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Hernando-Requejo</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Lapeña-Motilva</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Ogando-Durán</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Fouz-Ruiz</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Domingo-García</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>Verapamil as treatment for refractory status epilepticus secondary to PRES syndrome on a SARS-Cov-2 infected patient</article-title>
  <source>Seizure.</source>
  <volume>80</volume>
  <year>2020 Jun 6</year>
  <fpage>157</fpage>
  <lpage>158</lpage>
  <pub-id pub-id-type="pmid">32574838</pub-id>
 </element-citation>
</ref>
